Through 2021, The Number of Disease-Modifying Therapies Approved for The ... MarketWatch (press release) However, Decision Resources expects outstanding safety concerns will constrain the adoption of these potentially high-risk/high-reward therapies by a generally conservative neurologist prescriber base. Together with emerging anti-CD25 MAb daclizumab ... |
